|
1
|
Anastasiou D: Tumour microenvironment
factors shaping the cancer metabolism landscape. Br J Cancer.
116:277–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alfarouk KO: Tumor metabolism, cancer cell
transporters, and microenvironmental resistance. J Enzyme Inhib Med
Chem. 31:859–866. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Avantaggiati ML: Cancer metabolism as a
therapeutic target: Finding the right target(s) in the context of
tumor heterogeneity, evolution, and metabolic plasticity. Oncology.
27:474476–477. 2013.PubMed/NCBI
|
|
4
|
Bahrami A, Khazaei M, Hassanian SM,
ShahidSales S, Joudi-Mashhad M, Maftouh M, Jazayeri MH, Parizade
MR, Ferns GA and Avan A: Targeting the tumor microenvironment as a
potential therapeutic approach in colorectal cancer: Rational and
progress. J Cell Physiol. 233:2928–2936. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ackerman D and Simon MC: Hypoxia, lipids,
and cancer: Surviving the harsh tumor microenvironment. Trends Cell
Biol. 24:472–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brahimi-Horn MC and Pouysségur J: Hypoxia
in cancer cell metabolism and pH regulation. Essays Biochem.
43:165–178. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamada K, Saito M, Matsuoka H and Inagaki
N: A real-time method of imaging glucose uptake in single, living
mammalian cells. Nat Protoc. 2:753–762. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Annibaldi A and Widmann C: Glucose
metabolism in cancer cells. Curr Opin Clin Nutr Metab Care.
13:466–470. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adekola K, Rosen ST and Shanmugam M:
Glucose transporters in cancer metabolism. Curr Opin Oncol.
24:650–654. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Alfarouk KO, Verduzco D, Rauch C,
Muddathir AK, Adil HH, Elhassan GO, Ibrahim ME, David Polo Orozco
J, Cardone RA, Reshkin SJ, et al: Glycolysis, tumor metabolism,
cancer growth and dissemination. A new pH-based etiopathogenic
perspective and therapeutic approach to an old cancer question.
Oncoscience. 1:777–802. 2014.
|
|
11
|
Alfarouk KO, Verduzco D, Rauch C,
Muddathir AK, Bashir AH, Elhassan GO, Ibrahim ME, Orozco JD,
Cardone RA, Reshkin SJ, et al: Erratum: Glycolysis, tumor
metabolism, cancer growth and dissemination. A new pH-based
etiopathogenic perspective and therapeutic approach to an old
cancer question. Oncoscience. 2:3172014.
|
|
12
|
Frérart F, Sonveaux P, Rath G, Smoos A,
Meqor A, Charlier N, Jordan BF, Saliez J, Noël A, Dessy C, et al:
The acidic tumor microenvironment promotes the reconversion of
nitrite into nitric oxide: Towards a new and safe radiosensitizing
strategy. Clin Cancer Res. 14:2768–2774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Doherty JR and Cleveland JL: Targeting
lactate metabolism for cancer therapeutics. J Clin Invest.
123:3685–3692. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Justus CR, Dong L and Yang LV: Acidic
tumor microenvironment and pH-sensing G protein-coupled receptors.
Front Physiol. 4:3542013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato Y, Ozawa S, Miyamoto C, Maehata Y,
Suzuki A, Maeda T and Baba Y: Acidic extracellular microenvironment
and cancer. Cancer Cell Int. 13:892013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Koukourakis MI, Kakouratos C, Kalamida D,
Bampali Z, Mavropoulou S, Sivridis E and Giatromanolaki A:
Hypoxia-inducible proteins HIF1α and lactate dehydrogenase LDH5,
key markers of anaerobic metabolism, relate with stem cell markers
and poor post-radiotherapy outcome in bladder cancer. Int J Radiat
Biol. 92:353–363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marchiq I and Pouysségur J: Hypoxia,
cancer metabolism and the therapeutic benefit of targeting
lactate/H+ symporters. J Mol Med (Berl). 94:155–171.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bailey KM, Wojtkowiak JW, Hashim AI and
Gillies RJ: Targeting the metabolic microenvironment of tumors. Adv
Pharmacol. 65:63–107. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
LaValle CR, George KM, Sharlow ER, Lazo
JS, Wipf P and Wang QJ: Protein kinase D as a potential new target
for cancer therapy. Biochim Biophys Acta. 1806:183–192.
2010.PubMed/NCBI
|
|
20
|
Mikhalap SV, Kovalevska LM and Sydorenko
SP: The role of PKD family protein kinases in the regulation of
protein post-translational modification. Ukr Biokhim Zh. 80:16–24.
2008.(In Ukrainian).
|
|
21
|
Malhotra V and Campelo F: PKD regulates
membrane fission to generate TGN to cell surface transport
carriers. Cold Spring Harb Perspect Biol. 3:a0052802011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eisenberg-Lerner A and Kimchi A: PKD at
the crossroads of necrosis and autophagy. Autophagy. 8:433–434.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liou GY and Storz P: Protein kinase D
enzymes: Novel kinase targets in pancreatic cancer. Expert Rev
Gastroenterol Hepatol. 9:1143–1146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mikhalap SV, Shabelnyk MIu and Sydorenko
SP: Protein kinases of PKD family as a potential object of
translational research in oncology. Ukr Biokhim Zh (1999).
82:18–32. 2010.(In Ukrainian). PubMed/NCBI
|
|
25
|
No authors listed: Study reveals new drug
target for PKD. Nephrol News Issues. 30:162016.
|
|
26
|
Zhang T, Sell P, Braun U and Leitges M:
PKD1 protein is involved in reactive oxygen species-mediated
mitochondrial depolarization in cooperation with protein kinase Cδ
(PKCδ). J Biol Chem. 290:10472–10485. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qin XJ, Gao ZG, Huan JL, Pan XF and Zhu L:
Protein kinase D1 inhibits breast cancer cell invasion via
regulating matrix metalloproteinase expression. Eur J Gynaecol
Oncol. 36:690–693. 2015.PubMed/NCBI
|
|
28
|
Ochi N, Tanasanvimon S, Matsuo Y, Tong Z,
Sung B, Aggarwal BB, Sinnett-Smith J, Rozengurt E and Guha S:
Protein kinase D1 promotes anchorage-independent growth, invasion,
and angiogenesis by human pancreatic cancer cells. J Cell Physiol.
226:1074–1081. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rozengurt E: Protein kinase D signaling:
Multiple biological functions in health and disease. Physiology.
26:23–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jóźwiak P, Krześlak A, Bryś M and Lipińska
A: Glucose-dependent glucose transporter 1 expression and its
impact on viability of thyroid cancer cells. Oncol Rep. 33:913–920.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Teppo S, Sundquist E, Vered M, Holappa H,
Parkkisenniemi J, Rinaldi T, Lehenkari P, Grenman R, Dayan D,
Risteli J, et al: The hypoxic tumor microenvironment regulates
invasion of aggressive oral carcinoma cells. Exp Cell Res.
319:376–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pereira KM, Chaves FN, Viana TS, Carvalho
FS, Costa FW, Alves AP and Sousa FB: Oxygen metabolism in oral
cancer: HIF and GLUTs (Review). Oncol Lett. 6:311–316. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Marín-Hernández A, Gallardo-Pérez JC,
Ralph SJ, Rodríguez-Enríquez S and Moreno-Sánchez R: HIF-1alpha
modulates energy metabolism in cancer cells by inducing
over-expression of specific glycolytic isoforms. Mini Rev Med Chem.
9:1084–1101. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hay MP, Hicks KO and Wang J:
Hypoxia-directed drug strategies to target the tumor
microenvironment. Adv Exp Med Biol. 772:111–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Esteban MA and Maxwell PH: HIF, a missing
link between metabolism and cancer. Nat Med. 11:1047–1048. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Leo C, Giaccia AJ and Denko NC: The
hypoxic tumor microenvironment and gene expression. Semin Radiat
Oncol. 14:207–214. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Labiano S, Palazon A and Melero I: Immune
response regulation in the tumor microenvironment by hypoxia. Semin
Oncol. 42:378–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu C, Gao S, Qu Z and Zhang L: Tumor
microenvironment: Hypoxia and buffer capacity for immunotherapy.
Med Hypotheses. 69:590–595. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
No authors listed: Metabolism in cancer.
JAMA. 310:24622013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Camarda R, Williams J and Goga A: In vivo
reprogramming of cancer metabolism by MYC. Front Cell Dev Biol.
5:352017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cantor JR and Sabatini DM: Cancer cell
metabolism: One hallmark, many faces. Cancer Discov. 2:881–898.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Cornu M, Albert V and Hall MN: mTOR in
aging, metabolism, and cancer. Curr Opin Genet Dev. 23:53–62. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dang CV, Le A and Gao P: MYC-induced
cancer cell energy metabolism and therapeutic opportunities. Clin
Cancer Res. 15:6479–6483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liou GY, Storz P and Leitges M: A bright
future for protein kinase D1 as a drug target to prevent or treat
pancreatic cancer. Mol Cell Oncol. 3:e10354772015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Finger EC and Giaccia AJ: Hypoxia,
inflammation, and the tumor microenvironment in metastatic disease.
Cancer Metastasis Rev. 29:285–293. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Airley RE and Mobasheri A: Hypoxic
regulation of glucose transport, anaerobic metabolism and
angiogenesis in cancer: Novel pathways and targets for anticancer
therapeutics. Chemotherapy. 53:233–256. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cui XG, Han ZT, He SH, Wu XD, Chen TR,
Shao CH, Chen DL, Su N, Chen YM, Wang T, et al: HIF1/2α mediates
hypoxia-induced LDHA expression in human pancreatic cancer cells.
Oncotarget. 8:24840–24852. 2017.PubMed/NCBI
|
|
48
|
Matrone A, Grossi V, Chiacchiera F, Fina
E, Cappellari M, Caringella AM, Di Naro E, Loverro G and Simone C:
p38alpha is required for ovarian cancer cell metabolism and
survival. Int J Gynecol Cancer. 20:203–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
García-Cano J, Roche O, Cimas FJ,
Pascual-Serra R, Ortega-Muelas M, Fernández-Aroca DM and
Sánchez-Prieto R: p38 MAPK and Chemotherapy: We Always Need to Hear
Both Sides of the Story. Front Cell Dev Biol. 4:692016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brichkina A and Bulavin DV: Cancer
suppression by systemic inactivation of p38 MAPK. Oncotarget.
8:14275–14276. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Koodie L, Ramakrishnan S and Roy S:
Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38
MAPK pathway. Am J Pathol. 177:984–997. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Yan L, Cao X, Zeng S, Li Z, Lian Z, Wang
J, Lv F, Wang Y and Li Y: Associations of proteins relevant to MAPK
signaling pathway (p38 MAPK-1, HIF-1 and HO-1) with coronary lesion
characteristics and prognosis of peri-menopausal women. Lipids
Health Dis. 15:1872016. View Article : Google Scholar : PubMed/NCBI
|
